Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors

Cohort study (9,088 patients on an immune checkpoint inhibitor [ICI]) found 0.40% developed ICI‐myositis. Incidence was 0.31% in those on ICI monotherapy vs 0.94% in those on combination ICI therapy. Eight patients died. Optimal treatment strategies remain to be determined.

Source:

Arthritis & Rheumatology